A Phase 2/3 interventional study of Riboflavin 0.1% ophthalmic solution and pulsed light and Riboflavin 0.1% ophthalmic solution and non-pulsed light in Keratoconus and Corneal Ectasia, sponsored by Price Vision Group. Recruiting at 1 site in United States. Open to participants aged 10 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment
This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.
Subjects diagnosed with keratoconus or corneal ectasia are randomized to one of two corneal crosslinking light durations.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
This study's planned enrollment of 500 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Browse Keratoconus studies →Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with 0.1% riboflavin eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes
Combination Product: Riboflavin 0.1% ophthalmic solution and pulsed light
Treatment with 0.1% riboflavin eye drops non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes
Combination Product: Riboflavin 0.1% ophthalmic solution and non-pulsed light
Drug page: Riboflavin
Use of riboflavin 0.1% eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes
Drug page: Riboflavin
Use of riboflavin 0.1% eye drops and non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes
Change in maximum keratometry
assessed with corneal tomography
Time frame: 6 months
change in corrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
change in uncorrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
Plan to share: No — IPD may be shared upon individual request to the study contact
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Price Vision Group